Ibutilide Administration During Pulmonary Vein Ablation (IBAD-AFIB)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2012 by Ball Memorial Hospital
St. Jude Medical
Information provided by:
Ball Memorial Hospital
ClinicalTrials.gov Identifier:
First received: December 26, 2007
Last updated: January 27, 2012
Last verified: January 2012
To test the hypothesis that localized functional reentry maintains Afib in humans, ibutilide will be administered intravenously in patients undergoing an Afib ablation. The hypothesis of this study is that ibutilide will decrease the high frequency signals observed in Afib suggesting the presence of micro reentrant circuits as the basic mechanism of Afib, especially for the paroxysmal Afib group. The potential difference in response to the ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the underlying mechanism of Afib between these two groups.

Condition Intervention
Atrial Fibrillation
Pulmonary Vein Ablation
Drug: Ibutilide fumarate

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Atrial Fibrillation Mechanism Analysis Through Ibutilide Administration During Pulmonary Vein Ablation.

Resource links provided by NLM:

Further study details as provided by Ball Memorial Hospital:

Primary Outcome Measures:
  • To discern the basic mechanism of Afib by studying its response to Ibutilide administration. [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare the ibutilide response in patients with paroxysmal versus permanent Afib [ Time Frame: one year ] [ Designated as safety issue: No ]
  • To study the subgroup of patients that converted to sinus rhythm in order to identify various factors that may have increased their susceptibility to ibutilide. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • To improve the current results of pulmonary vein isolation by performing a procedure guided by ablation of high dominant frequency areas. [ Time Frame: One year ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: October 2007
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Ibutilide fumarate
    During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients to be scheduled for atrial fibrillation radio frequency ablation
  • paroxysmal, permanent symptomatic atrial fibrillation refractory to conventional treatment
  • symptomatic atrial fibrillation that do not want or desire to take medication or undergo cardioversion
  • patients on antiarrhythmics that can be discontinued 5 half lifes prior to the procedure except for Amiodarone

Exclusion Criteria:

  • patients with recent major hemorrhage (within 6 months)
  • patients with a coagulopathy
  • patients who are pregnant or breast feeding
  • patients with acute congestive heart failure
  • patients with hypokalemia or hyperkalemia
  • patients with a prolonged QTc > 440mms
  • patients with polymorphic ventricular tachycardia secondary to antiarrhythmic class III and class I
  • patients with left ventricular dysfunction < 40%
  • patients with a history of recent MI (< 1 month)
  • patients with a history of an angioplasty of < 1 month
  • patients with a history of coronary artery bypass grafting surgery of < 3 months.
  • patients with a history of chronic renal failure or a creatinine clearance of < 30ml/m
  • patients with a history of stroke of < 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00589992

Contact: Antonio Navarrete, MD 765-281-2000 annavarr@mac.com
Contact: Sherry Adair, RN 765-254-4761 skadair@medicalconsultantspc.com

United States, Indiana
Medical Consultants, P.C. Recruiting
Muncie, Indiana, United States, 47303
Contact: Sherry Adair, RN    765-254-4761    skadair@medicalconsultantspc.com   
Principal Investigator: Antonio Navarrete, MD         
Sponsors and Collaborators
Ball Memorial Hospital
St. Jude Medical
Principal Investigator: Antonio Navarrete, MD Staff Physician, Ball Memorial Hospital
  More Information

Responsible Party: Antonio Navarrete, MD, Medical Consultants, P.C.
ClinicalTrials.gov Identifier: NCT00589992     History of Changes
Other Study ID Numbers: BMH study #762 
Study First Received: December 26, 2007
Last Updated: January 27, 2012
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Anti-Arrhythmia Agents

ClinicalTrials.gov processed this record on May 26, 2016